H1 2017

Tecan with significant increase in order entry and strong sales growth in the Life Sciences Business

Tecan Group AG / H1 2017: Tecan with significant increase in order entry and strong sales growth in the Life Sciences Business . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Financial results for the first half of 2017

• Order entry of CHF 291.2 million (H1 2016: CHF 250.6 million)
  • Growth of 16.7% in local currencies or 16.2% in Swiss francs
  • Double-digit increase in both business segments
• Sales of CHF 253.3 million (H1 2016: CHF 235.3 million)
  • Growth of 8.0% in local currencies or 7.7% in Swiss francs
  • Organic growth of 3.4% in local currencies despite higher basis for comparison due to positive one-time effect in the prior-year period
  • Strong growth in the Life Sciences Business
• Operating profit before depreciation and amortization (EBITDA) of CHF 41.3 million (H1 2016: CHF 37.9 million)
  • EBITDA margin of 16.3% (H1 2016: 16.1%), including acquisition-related costs and reduced margins associated with acquisitions
• Net profit of CHF 25.7 million (H1 2016: CHF 23.5 million)
  • Net profit margin including integration costs of 10.1% (H1 2016: 10.0%)
  • Increase in earnings per share by 8.8% to CHF 2.22 (H1 2016: CHF 2.04)
• Cash flow from operating activities of CHF 31.7 million (H1 2016: CHF 64.9 million; including a reimbursement of development costs)
• Outlook for full-year 2017 confirmed

Operating performance in the first half of 2017

• Considerable progress with the integration of SPEware Corporation (now Tecan SP, Inc.), which was acquired in September 2016
• Acquisition of Pulssar Technologies S.A.S. in February 2017 to expand the technology portfolio in the Partnering Business
• Launch of a new platform development project with DiaSorin in the Partnering Business

Männedorf, Switzerland, August 16, 2017 - The Tecan Group (SIX Swiss Exchange: TECN) posted a significant increase in order entry and strong sales growth in the Life Sciences Business in the first half of 2017.